Insider · CIK 0001296995

Sommadossi Jean-Pierre

Reports to the SEC for 4 companies · BOSTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001296995

Forms 4 and 5

Insider transactions

40 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-02-03	AVIRAtea Pharmaceuticals, Inc.M Exercise/Conversion	Director, President, CEO, and Chairman	MExercise/Conversion	+300K sh	$1.24	+$372K	767,830
2026-02-03	AVIRAtea Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, President, CEO, and Chairman	MExercise/Conversion	−300K sh	—	—	0
2026-01-31	AVIRAtea Pharmaceuticals, Inc.M Exercise/Conversion	Director, President, CEO, and Chairman	MExercise/Conversion	+273K sh	—	—	573,923
2026-01-31	AVIRAtea Pharmaceuticals, Inc.F Tax Payment	Director, President, CEO, and Chairman	FTax Payment	−106K sh	$4.24	−$450K	467,830
2026-01-31	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, President, CEO, and Chairman	MExercise/Conversion	−173K sh	—	—	0
2026-01-31	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, President, CEO, and Chairman	MExercise/Conversion	−99.5K sh	—	—	0
2025-01-31	AVIRAtea Pharmaceuticals, Inc.M Exercise/Conversion	Director, President, CEO, and Chairman	MExercise/Conversion	+173K sh	—	—	290,024
2025-01-31	AVIRAtea Pharmaceuticals, Inc.A Award	Director, President, CEO, and Chairman	AAward	+99.5K sh	—	—	389,541
2025-01-31	AVIRAtea Pharmaceuticals, Inc.F Tax Payment	Director, President, CEO, and Chairman	FTax Payment	−88.6K sh	$3.06	−$271K	300,940
2025-01-31	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, President, CEO, and Chairman	MExercise/Conversion	−173K sh	—	—	173,466
2025-01-31	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Director, President, CEO, and Chairman	AAward	+99.5K sh	—	—	99,518
2025-01-31	AVIRAtea Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director, President, CEO, and Chairman	AAward	+440K sh	—	—	440,000
2024-09-19	AVIRAtea Pharmaceuticals, Inc.S Sale	Director, President, CEO, and Chairman	SSale	−1,841 sh	$4.00	−$7,367.498	5,866,025
2024-09-18	AVIRAtea Pharmaceuticals, Inc.S Sale	Director, President, CEO, and Chairman	SSale	−22.2K sh	$4.03	−$89.5K	5,867,866
2024-09-17	AVIRAtea Pharmaceuticals, Inc.S Sale	Director, President, CEO, and Chairman	SSale	−33.9K sh	$4.05	−$137K	5,890,053
2024-06-05	AVIRAtea Pharmaceuticals, Inc.S Sale	Director, President, CEO, and Chairman	SSale	−1,006 sh	$4.00	−$4,024	5,923,994
2024-02-01	AVIRAtea Pharmaceuticals, Inc.S Sale	Director, President, CEO, and Chairman	SSale	−56.9K sh	$3.85	−$219K	116,557
2024-01-31	AVIRAtea Pharmaceuticals, Inc.M Exercise/Conversion	Director, President, CEO, and Chairman	MExercise/Conversion	+173K sh	—	—	173,467
2024-01-31	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, President, CEO, and Chairman	MExercise/Conversion	−173K sh	—	—	346,933
2024-01-31	AVIRAtea Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director, President, CEO, and Chairman	AAward	+448K sh	—	—	448,000
2023-03-01	ABG Acquisition Corp. IClass B ordinary sharesD Disposition to Issuer	Director	DDisposition to Issuer	−32.5K sh	—	—	0
2023-01-31	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Director, President, CEO, and Chairman	AAward	+520K sh	—	—	520,400
2023-01-31	AVIRAtea Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director, President, CEO, and Chairman	AAward	+729K sh	—	—	728,600
2022-01-31	AVIRAtea Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director, President, CEO, and Chairman	AAward	+378K sh	—	—	378,033
2021-06-28	KZRKezar Life Sciences, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+26K sh	—	—	26,000
2021-01-29	AVIRAtea Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director, President, CEO, and Chairman	AAward	+640K sh	—	—	640,000
2020-11-03	AVIRAtea Pharmaceuticals, Inc.C Conversion	Director, President, CEO, and Chairman	CConversion	+750K sh	—	—	5,925,000
2020-11-03	AVIRAtea Pharmaceuticals, Inc. · Series A Convertible Preferred StockC Conversion	Director, President, CEO, and Chairman	CConversion	−750K sh	—	—	0
2020-06-24	KZRKezar Life Sciences, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+8,896 sh	—	—	8,896
2019-06-25	KZRKezar Life Sciences, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+8,896 sh	—	—	8,896
2018-06-25	KZRKezar Life Sciences, Inc.C Conversion	Director	CConversion	+52.6K sh	—	—	143,182
2018-06-25	KZRKezar Life Sciences, Inc.C Conversion	Director	CConversion	+35.3K sh	—	—	178,440
2018-06-25	KZRKezar Life Sciences, Inc. · Series A Convertible Perferred StockC Conversion	Director	CConversion	−52.6K sh	—	—	0
2018-06-25	KZRKezar Life Sciences, Inc. · Series B Convertible Perferred StockC Conversion	Director	CConversion	−35.3K sh	—	—	0
2010-02-10	IDENIX PHARMACEUTICALS INCEmployee Stock Option (Right to Buy)A Award	Director, President, CEO, Chairman	AAward	+400K sh	—	—	400,000
2009-02-13	IDENIX PHARMACEUTICALS INCEmployee Stock Option (Right to Buy)A Award	Director, President, CEO, Chairman	AAward	+400K sh	—	—	400,000
2007-06-01	IDENIX PHARMACEUTICALS INCEmployee Stock Option (right to buy)A Award	Director, President, CEO, Chairman	AAward	+150K sh	—	—	150,000
2005-02-28	IDENIX PHARMACEUTICALS INCEmployee Stock Option (right to buy)A Award	Director, President, CEO, Chairman	AAward	+150K sh	—	—	150,000
2004-08-26	IDENIX PHARMACEUTICALS INCM Exercise/Conversion	Director, President, CEO, Chairman	MExercise/Conversion	+43.8K sh	$8.50	+$372K	2,007,614
2004-08-26	IDENIX PHARMACEUTICALS INCEmployee Stock Option (right to buy)M Exercise/Conversion	Director, President, CEO, Chairman	MExercise/Conversion	−43.8K sh	—	—	56,250

Recent filings

Accepted (ET)
Feb 34
Sommadossi Jean-Pierre0001193125-26-036268
SEC(opens sec.gov)
Feb 44
Sommadossi Jean-Pierre0000950170-25-013846
SEC(opens sec.gov)
Sep 194
Sommadossi Jean-Pierre0000950170-24-108233
SEC(opens sec.gov)
Jun 74
Sommadossi Jean-Pierre0000950170-24-070965
SEC(opens sec.gov)
Feb 24
Sommadossi Jean-Pierre0000950170-24-010972
SEC(opens sec.gov)

Companies

Address

225 FRANKLIN STREET SUITE 2100

BOSTON, MA, 02110